Literature DB >> 29564533

Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension.

Vikas Pathak1, Robert Aris2, Brian C Jensen3, Wei Huang3, Hubert James Ford2.   

Abstract

BACKGROUND: Plasma pro-BNP (brain natriuretic peptide) levels are often elevated in response to right ventricular (RV) volume and pressure overload, parameters potentially affected by exercise. Plasma pro-BNP levels change in association with long-term changes in pulmonary hemodynamics, thereby serving as a potential biomarker in pulmonary arterial hypertension (PAH). The 6-min Walk Test (6MWT) and pro-BNP level are often checked in a single office visit. There is no universal standard for measuring Pro-BNP levels relative to the timing of the 6MWT. Based on the studies in normal subjects indicating that pro-BNP levels changes after exercise, we hypothesized that the pro-BNP might rise after the 6MWT in PAH patients, potentially impacting clinical decisions.
METHODS: Patients at our center with WHO Group 1 PAH on active therapy at a stable dose for 30 days or more were enrolled. After resting the patient for 30 min, blood was drawn for baseline pro-BNP and a 6MWT was performed. Pro-BNP levels were drawn immediately after the 6MWT and 1 and 2 h later. Pro-BNP was measured using a commercially available ELISA kit. The levels before exercise and after exercise were compared using student's paired t tests.
RESULTS: There were 17 females and 3 male subjects. The mean age was 53 ± 11 years. Seven patients had systemic lupus erythematosus-related PAH, six had idiopathic PAH, three had scleroderma, three had portopulmonary hypertension, and one had HIV-related PAH. The mean PA pressure was 50 ± 15 mmHg with a mean pulmonary vascular resistance of 10 ± 4 Wood units. The majority of the patients were on multimodality PAH therapy, including parenteral prostacyclins. Mean 6MWT distance was 377 ± 140 m. In 14/20 patients, the pro-BNP level increased immediately after the 6MWT; in 12/20 patients, the pro-BNP level was elevated at 1 h post exercise. In the majority of the patients, the pro-BNP fell to baseline 2 h post 6MWT.
CONCLUSION: There appears to be a trend of pro-BNP level increasing immediately after exercise and continuing to be elevated at 1 h. Pro-BNP levels then return to baseline at 2 h post 6MWT.

Entities:  

Keywords:  Pro-BNP; Pulmonary hypertension; Six-min walk test

Mesh:

Substances:

Year:  2018        PMID: 29564533     DOI: 10.1007/s00408-018-0111-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  27 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 2.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

3.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.

Authors:  Anna Fijalkowska; Marcin Kurzyna; Adam Torbicki; Grzegorz Szewczyk; Michal Florczyk; Piotr Pruszczyk; Monika Szturmowicz
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

4.  Exercise pathophysiology in patients with primary pulmonary hypertension.

Authors:  X G Sun; J E Hansen; R J Oudiz; K Wasserman
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

5.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

Authors:  S Miyamoto; N Nagaya; T Satoh; S Kyotani; F Sakamaki; M Fujita; N Nakanishi; K Miyatake
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

6.  Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

Authors:  T W Higenbottam; A Y Butt; A T Dinh-Xaun; M Takao; G Cremona; S Akamine
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

7.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

Review 8.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more
  3 in total

1.  Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension.

Authors:  Jenny Y Chen; Megan Griffiths; Jun Yang; Melanie K Nies; Rachel L Damico; Catherine E Simpson; R Dhananjay Vaidya; Stephanie Brandal; D Dunbar Ivy; Eric D Austin; William C Nichols; Michael W Pauciulo; Katie Lutz; Erika B Rosenzweig; Russel Hirsch; Delphine Yung; Allen D Everett
Journal:  J Pediatr       Date:  2020-08       Impact factor: 4.406

Review 2.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

3.  Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension.

Authors:  Catherine E Simpson; Jenny Y Chen; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie Nies; Megan Griffiths; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Katie A Lutz; Anna W Coleman; Eric D Austin; Dunbar D Ivy; William C Nichols; Allen D Everett
Journal:  Eur Respir J       Date:  2020-04-16       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.